• Market

Morepen Labs Catches Pharma Sector Uptrend in Q1 FY 2019-20. Company’s Net Profit Rises by a Whopping 256 Percent Led by a Significant Jump in its APIs Exports

New Delhi, Delhi, India Highlights Q1 FY 2019-20 (Standalone): Net Sales Revenue recorded a pure organic growth of 25.4 per…

Morepen Labs begins FY 2018-19 with a Sound Performance in the First Quarter

Company reports 93 percent rise in its consolidated net profit and 26 percent rise in its consolidated net sales revenue…

Twin USFDA Approvals for Morepen Labs’ Bulk Drugs (API) Facilities

Baddi facility gets US FDA nod for bulk drug “Atorvastatin” and Masulkhana facility for “Montelukast” New Delhi, August 05, 2018:…